Kaléo is a pharmaceutical company based in Richmond, Virginia, founded in 2005 by twin brothers Dr. Eric Edwards and Evan Edwards. The company specializes in innovative drug-delivery device technology, particularly auto-injectors, and holds over 200 patents in this field.

Kaléo is recognized for its AUVI-Q® epinephrine auto-injector, which provides doses of 0.15 mg and 0.3 mg for treating allergic anaphylaxis. It also developed the AUVI-Q® for infants and toddlers, the first FDA-approved auto-injector designed for this age group, delivering a 0.1 mg dose. The company's Aerio Auto-Injection Platform supports these products, ensuring reliable and user-friendly emergency treatment options. In Canada, Kaléo markets its auto-injector as Allerject.

Acquired by Marathon Asset Management in 2021, Kaléo continues to focus on providing innovative solutions for patients requiring emergency treatment for severe allergic reactions and opioid overdoses, enhancing patient security and peace of mind.